supported by a grant from the National Key R&D Program of China(2023YFC3041600 YW,the National Natural Science Foundation of China(82025001 JZ,92369113 YW,82172240 YW);Guangdong Basic and Applied Research Projects(2023B1515020040 YW,2021B1515130005 JZ,2021B1212030016 JD,2021A1111100009 JD);Science and Technology Planning Project of Guangzhou City(2023A04J1279 LZ);ZhongNanShan Medical Foundation of Guangdong Province(ZNSA-2020013 JZ);the Science and Technology Project of General Administration of Customs,P.R.China(2023HK065 LZ);State Key Laboratory of Respiratory Disease(SKLRD-Z-202214,SKLRD-OP-202309 YW,SKLRD-Z-202411 LZ);the Self-supporting Program of Guangzhou Laboratory(GZNL2023A01006,SRPG22-001);Guangzhou Medical University(YP2022005 YW);Korea Institute of Planning and Evaluation for Technology in Food,Agriculture and Forestry(IPET)through Animal Disease Management Technology Advancement Support Program,funded by the Ministry of Agriculture,Food and Rural Affairs(MAFRA)(122012-2,122060-2 JZ);the National Clinical Research Center for Respiratory Disease(BRD-NCRCRD,Guangzhou,Southern China).Patronus Biotech is a company researching virus-like particle display technology and vaccines.Yu Zhou and Jing Jin are named inventors on a patent invention relating to the described novel SARS-CoV-2 virus-like particle vaccine.All BALB/c mouse experiments complied with relevant ethical regulations for animal research and were approved by the LUYE PHARMA Animal Experimentation Ethics Committee.The K18-hACE2 mouse experiment was reviewed and approved by the Institutional Animal Care and Use Committees of Guangzhou Medical University(2023-0451).All authors declare that they have no conflict of interests.
Dear Editor,The newly emerged severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)Omicron subvariants(XBB.1,EG.5 and JN.1)and sublineages have been circulating globally with superior growth advantages over othe...
supported by grants from Key Research&Development Project of Nanhua Biomedical Co.,Ltd.(No.H202191490139);National Natural Science Foundation of China(No.31872866);China Postdoctoral Science Foundation(Nos.2021M701160 and 2022M721101);Funds of Hunan university(521119400156).
Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2),the pathogen responsible for coronavirus disease 2019(COVID-19),continues to evolve,giving rise to more variants and global reinfections.Previous research ha...
supported by the Science and Technology Program of Zhejiang Province (#2022C03017);Key Research and Development Program of Zhejiang Province (#2021C03044);Major Health Science and Technology Projects of Zhejiang Province (#WKJ-ZJ-2105);National Key R&D Program of China (#2021YFC2301200).
Dear Editor,The coronavirus disease 2019(COVID-19)pandemic has resulted in 763 million cases and over 6 million deaths as of April 2023.Given the high prevalence and widespread distribution of coronaviruses,the geneti...
Guangzhou Health Science and Technology Project(20201A011078);Guangzhou Science and Technology Project(202102010094);Guangdong Basic and Applied Basic Research Foundation(2021A1515012550);Clinical research project of Guangzhou Medical University Second Affiliated Hospital(2021-LCYJ-05);Guangdong Medical Research Fund(A2022255);Key Clinical Specialty of Guangzhou Medical University(0F03031);Guangzhou Laboratory(EKPG21-30-3);Guangzhou key discipline of urology.The funding sources had no role in the study design,data collection,analysis,interpretation,or writing of the report.
Homologous booster,heterologous booster,and Omicron variants breakthrough infection(OBI)could improve the humoral immunity against Omicron variants.Questions concerning about memory B cells(MBCs)and T cells immunity a...
supported by grants from the National Key R&D Program of China(2021YFC2301700);National Natural Science Foundation of China(82061138021);the Key Biosafety Science and Technology Program of Hubei Jiangxia Laboratory(JXBS001);Hubei Natural Science Foundation for Distinguished Young Scholars(2021CFA050).
Neutralizing monoclonal antibodies(mAb)are a major therapeutic strategy for the treatment of severe acute respiratory syndrome coronavirus-2(SARS-CoV-2)infection.The continuous emergence of new SARS-CoV-2 variants wor...
supported by funding from Beijing Natural Science Foundation-Haidian Primitive Innovation Joint fund(L192008);the National Key R&D Program(2020YFA0707500,2018YFA0900801,2021YFA1301400);the National Natural Science Foundation of China(31872730 and 32070947)
Dear Editor,The COVID-19 pandemic, which is caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2), has led to millions of lives lost worldwide. The trimeric spike protein(S) decorating the membrane sur...
supported by the National Natural Science Foundation of China (82041001, 81761128020)
The prevalence of SARS-CoV-2 variants of concern(VOCs) is still escalating throughout the world. However, the level of neutralization of the inactivated viral vaccine recipients’ sera and convalescent sera against al...
supported by National Key Research and Development Program of China(2021YFC2600200,2017YFA0205100)。
Multiple new variants of severe acute respiratory syndrome coronavirus 2(SARS-Co V-2)have constantly emerged,as the delta and omicron variants,which have developed resistance to currently gained neutralizing antibodie...
supported by the National Science and Technology Major Project(2018ZX10711-001)(2017YFA0205100)。
Severe acute respiratory syndrome coronavirus 2(SARS-Co V-2)has precipitated multiple variants resistant to therapeutic antibodies.In this study,12 high-affinity antibodies were generated from convalescent donors in e...
Hepatitis C virus(HCV)is still one of the main causes of liver disease worldwide.Metabolic disorders,including nonalcoholic fatty liver disease(NAFLD),induced by HCV have been shown to accelerate the progression of fi...